Gene Expression Analysis Market Segmented By Kits & Reagents, DNA Clips Product with Low – to Mid-Plex, High-Plex Capacity
Industry: Healthcare
Published Date: May-2022
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 170
Report ID: PMRREP17995
The global gene expression market is slated to be worth US$ 4.49 Bn by the year 2022 at a CAGR of 8.4% between 2022 and 2028.
| Attribute | Key Insights |
|---|---|
|
Gene Expression Therapy Market (2022) |
US$ 4.49 Bn |
|
Projected Market Value (2028) |
US$ 7.28 Bn |
|
Global Market Growth Rate (2022-2028) |
8.4% CAGR |
|
Share in Drug Discovery Market |
7.9% |
The gene expression analysis market, by type of product, has kits & reagents holding the largest market share (57.4%).
Gene expression analysis usually comes across as study of the pattern in which genes get transcribed for synthesizing the functional gene products – protein products or functional RNA species. This study, i.e. study of the regulation of genes makes way for insights into usual cellular processes. An interesting thing to know is that gene expression analysis could be done at any of the levels at which regulation of gene expression is done – post-translational, translational, post-transcriptional, and transcriptional. Illumina’s NovaSeq Series have made a mark with being cost-effective.
“Brazil, India, China, and Qatar to hold the baton”
Emerging economies like India and Brazil are poised to keep the cash registers running for gene expression analysis market in the forecast period. This could be credited to the fact that numerous established players are inking collaborative agreements with the organizations in these countries. This could be exemplified with partnership between KingMed Diagnostics and Illumina in January 2018 for developing next-generation sequencing-based oncology and the hereditary disease diagnostics (on the basis of MiniSeq technology) for the market of China.
India-based companies have also been receiving funds from investors across the globe for tabling advanced and new-fangled services in market. Core Diagnostics Pvt. Ltd. is being funded by F-Prime Capital Partners and Eight Roads Ventures. There are the other countries like Singapore and Qatar witnessing stupendous developments in their personalized medicine and genomics sectors. The QNRF (Qatar National Research Fund) and Qatar Biobank, since the year 2017, are into collaboration with QGP (Qatar Genome Project) pertaining to annual grant program known as PPM (Pathway Towards Personalized Medicine). The objective is that of supporting and encouraging genetic research activities in Qatar. On the similar grounds, Genome Asia 100K is an initiative taken by Macrogen, Inc. at Nanyang Technological University.
“lack of Funds and Skillset to restrain”
The initial investment in gene expression analysis is pretty high. As such, the developing economies would certainly think twice before getting into gene expression analysis. Plus, in spite of technological advances, the interpretation of analysis in toxicogenomics, diagnostics, and pharmacogenomics still depends on reader. It is a known fact that higher complexities coupled with in-depth knowledge are the mandates of genomics. However, shortage faced on this part is hampering the results. As per Shoreline Community College, it’s high time that immune-biotechnology training gets started all across the US, which is inclusive of work in molecular biology.
“Research-oriented Upswing Expected”
The outbreak of Covid-19 has resulted in upswing in gene expression analysis market, as relentless efforts are being made to gain insights into the cellular processes like differentiation and pathological or abnormal processes. This scenario is expected to persist even in the upcoming period, with the only difference being that the ailments could be different herein.
The key players in life sciences and clinical diagnostics, since the last few years, have shown interests in gene expression analysis. As such, they are engaging in organic as well as inorganic modes of expansion to stay afloat.
| Attribute | Details |
|---|---|
|
Forecast Period |
2022-2028 |
|
Historical Data Available for |
2015-2021 |
|
Market Analysis |
US$ Mn/Bn for Value |
|
Key Regions Covered |
|
|
Key Countries Covered |
|
|
Key Market Segments Covered |
|
|
Key Companies Profiled |
|
|
Pricing |
Available upon Request |
Gene Expression Analysis Market by Type of Product
Gene Expression Analysis Market by Capacity
Gene Expression Analysis Market by Application
Gene Expression Analysis by Technology
Gene Expression Analysis Market by Region
To know more about delivery timeline for this report Contact Sales
The gene expression analysis Market is expected to be worth US$ 4.49 Bn in the year 2022 and grow 1.8 times by the year 2028.
The market for gene expression analysis is expected to reach US$ 7.28 Bn by 2028, expanding at a CAGR of 8.4%.
Kits & reagents account for 57.4% of the market share.
Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., General Electric Company, Illumina, Inc., Luminex Corporation, Oxford Gene Technology IP, PerkinElmer, Inc., QIAGEN NV, Roche Holding AG, and Thermo Fisher Scientific, Inc.
He gene expression analysis market accounts for 7.9% of the parent market share (in drug discovery market).
